2:45 p.m.: Is the Micra Intracardiac Pacemaker Suitable for All Adult Sizes and Ages? (Micra TPS, Room 205A)
2:45 p.m.: The Evera MRI Study (Evera MRI ICD Late-Breaking Clinical Trials I, Ballroom West)

Friday, May 15
8 a.m.: Performance of a Miniaturized Transcatheter Pacing System: First-In-Human Experience (Micra TPS Late-Breaking Clinical Trials II, Ballroom West)

9:30 a.m.: Serial Post-Implant Left Ventricular Vector Selection and Device Longevity (Attain Performa system, EPicenter, Exhibit Hall)
1:45 p.m.: Efficacy of a Bioabsorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients (TYRX envelope, Room 210b)
2:30 p.m.: Citadel/Centurion Study Results (TYRX envelope, Room 205A)

Saturday, May 16
9:30 a.m.: Effectiveness of Steroid-Eluting Electrodes on Quadripolar Left Ventricular (LV) Leads - Results from a Large Worldwide Clinical Trial (Attain Performa system, Grand Ballroom Foyer, Level 3)

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Ryan Mathre
Public Relations
+1-763-514-9625

Jeff Warren
Investor Relations
+1-763-505-2696

Back to HCB News

More HCB News